Avalyn Pharma Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVLN research report →
Range $51 – $80
Price Chart
About the company
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs).
- CEO
- Lyn Baranowski
- IPO
- 2026
- Employees
- 55
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on AVLN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.26B
- P/E
- -11.22
- PEG
- 0.22
- P/S
- 0.00
- P/B
- 3.40
- EV/EBITDA
- -9.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -164.68%
- ROIC
- -30.42%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-91,292,000
- Net Income
- $-85,204,000-71.3%
- EPS
- $-2.04-71.4%
- OCF Growth
- -68.5%
- FCF Growth
- -68.8%
- 52W High
- $40.17
- 52W Low
- $22.24
- 50D MA
- $28.03
- 200D MA
- $29.87
- Beta
- -1.13
- RSI (14)
- 51
- Avg Volume
- 352.09K
No earnings-call transcripts are available for AVLN yet.
- Free Float
- 32.6%
- Shares Outstanding
- 44.52M
- Float Shares
- 14.52M
of shares held by institutions
95 13F filers
Buy/sell ratio 0.22. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 6.19M | ▲ 350.74K |
| Novo Holdings A/S | 3.45M | ▼ 434.10K |
| Sr One Capital Management, LP | 3.31M | 0 |
| Perceptive Advisors LLC | 2.68M | 0 |
| Montanova Capital, LLC | 2.50M | 0 |
| Nvp Associates, LLC | 2.27M | 0 |
| Wellington Management Group Llp | 2.10M | ▼ 97.13K |
| Price T Rowe Associates Inc | 1.81M | ▲ 79.72K |
| T. Rowe Price Investment Management, Inc. | 1.76M | ▲ 158.83K |
| Catalio Capital Management, LP | 1.70M | ▲ 23.02K |
| Eventide Asset Management, LLC | 1.38M | 0 |
| Bellevue Group AG | 1.35M | 0 |
Held by 173 ETFs
Biggest fund positions in AVLN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Lazarus Howard | other | 13,300 |
| Nov 17, 26 | Lazarus Howard | other | 13,300 |
| Nov 17, 26 | Lazarus Howard | sell | 11,023 |
| Nov 17, 26 | Lazarus Howard | sell | 2,066 |
| Nov 17, 26 | Lazarus Howard | sell | 211 |
| Nov 17, 26 | Baranowski Lyn | other | 45,300 |
| Nov 18, 26 | Baranowski Lyn | other | 7,200 |
| Nov 17, 26 | Baranowski Lyn | other | 45,300 |
| Nov 18, 26 | Baranowski Lyn | other | 7,200 |
| Nov 17, 26 | Baranowski Lyn | sell | 39,600 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVLN coverage
Recent articles, reports, and earnings notes.
No research on AVLN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVLN report →Avalyn Pharma: The Tolerability Budget Is The Real Battleground In Pulmonary Fibrosis
seekingalpha.com · Nov 19
Avalyn Pharma Inc. (AVLN) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
seekingalpha.com · Nov 11
Avalyn to Present at Upcoming Investor Conferences
globenewswire.com · Nov 3
Avalyn Pharma Inc. (NASDAQ:AVLN) Stock Now Rated “Moderate Buy” by Wall Street Analysts
defenseworld.net · Oct 1
Avalyn Publishes Phase 1 Data Highlighting AP02's Lung-Targeted Delivery and Encouraging Safety Profile
globenewswire.com · Sep 21
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
globenewswire.com · Sep 16
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
globenewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.